You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – China's National Medical Products Administration (NMPA) on Wednesday granted conditional approval for Astellas' gilteritinib (Xospata) to treat FLT3-mutated, relapsed or refractory acute myeloid leukemia.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.